Abiomed (ABMD) Halted Ahead of FDA Meeting on Blood Pumps
- Wall Street rallies as OPEC reaches output deal
- Pier 1 Imports (PIR) Reports In-Line Q2 EPS; Comps Fall 4.3%
- Intra-Cellular Therapies (ITCI) Announces ITI-007 Phase 3 Missed Primary Endpoint in Schizophrenia
- After-Hours Stock Movers 09/28: (AEGR) (PIR) (GSAT) Higher; (ITCI) (ATNM) (PRGS) Lower (more...)
Abiomed, Inc. (NASDAQ: ABMD) halted ahead of FDA advisory committee meeting over nonroller-type cardiopulmonary bypass blood pumps.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abiomed (ABMD): Japan Approval Opens Large Market For Heart Pumps - Leerink
- Aegerion Pharma (AEGR) Surges on Japanese Approval of JUXTAPID
- Intra-Cellular Therapies (ITCI) trading halted with news pending